Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
The Blood-brain Barrier00:49

The Blood-brain Barrier

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Australian and New Zealand Glaucoma Society (ANZGS) Consensus on Interventional Glaucoma.

Clinical & experimental ophthalmology·2026
Same author

Intravitreal photoswitch therapy in advanced retinitis pigmentosa: a phase 1 open-label trial.

Nature medicine·2026
Same author

Immunohistochemical optimization of a panel of antibodies against amyloid precursor protein for immunodetection of axonal injury in neurologic diseases of sheep.

Veterinary pathology·2026
Same author

Investigation into the use of a chitosan scaffold for tarsal plate substitution in eyelid reconstruction.

Regenerative biomaterials·2025
Same author

A Multitrait Polygenic Risk Score for Open-Angle Glaucoma Stratifies Risk of Pigmentary Glaucoma in Pigment Dispersion Syndrome.

Ophthalmology. Glaucoma·2025
Same author

Laser-induced histopathological changes to the retina: A review.

Survey of ophthalmology·2025

Related Experiment Video

Updated: Jul 2, 2026

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice
09:26

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

Bioenergetic-based neuroprotection and glaucoma.

Michael S Schober1, Glyn Chidlow, John Pm Wood

  • 1South Australian Institute of Ophthalmology, Adelaide, South Australia, Australia. michael.schober@imvs.sa.gov.au

Clinical & Experimental Ophthalmology
|August 15, 2008
PubMed
Summary

Primary open-angle glaucoma (POAG) involves retinal ganglion cell death. This review explores bioenergetic neuroprotection strategies, like enhancing cellular energy supply, to potentially treat POAG and prevent vision loss.

More Related Videos

An Ex Vivo Explant Model for Studying Glial Interactions in the Mouse Retina
09:46

An Ex Vivo Explant Model for Studying Glial Interactions in the Mouse Retina

Published on: July 15, 2025

Morphometric Analyses of Retinal Sections
14:33

Morphometric Analyses of Retinal Sections

Published on: February 19, 2012

Related Experiment Videos

Last Updated: Jul 2, 2026

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice
09:26

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

An Ex Vivo Explant Model for Studying Glial Interactions in the Mouse Retina
09:46

An Ex Vivo Explant Model for Studying Glial Interactions in the Mouse Retina

Published on: July 15, 2025

Morphometric Analyses of Retinal Sections
14:33

Morphometric Analyses of Retinal Sections

Published on: February 19, 2012

Area of Science:

  • Ophthalmology
  • Neuroscience
  • Cellular Biology

Background:

  • Primary open-angle glaucoma (POAG) is an optic neuropathy causing vision loss due to retinal ganglion cell death.
  • Current treatments focus on lowering intraocular pressure, but are insufficient for some patients.
  • Pathogenesis of POAG may involve energy failure at the optic nerve head.

Purpose of the Study:

  • To review potential bioenergetic neuroprotection strategies for the retina in glaucoma.
  • To explore methods that enhance neuronal energy supply as a therapeutic approach.

Main Methods:

  • Review of existing literature on bioenergetic neuroprotection in neurodegenerative diseases.
  • Focus on strategies applicable to retinal cells in glaucoma models.
  • Discussion of methods including cellular energy buffering, mitochondrial membrane stabilization, and free radical scavenging.

Main Results:

  • Bioenergetic neuroprotection has shown success in animal models of other neurodegenerative diseases.
  • These strategies have been relatively unexplored in glaucoma models.
  • Potential approaches involve enhancing cellular energy buffering, reducing mitochondrial permeability, and antioxidant effects.

Conclusions:

  • Bioenergetic strategies offer a promising, yet underexplored, avenue for neuroprotection in POAG.
  • Enhancing neuronal energy supply could be a novel therapeutic target for preventing vision loss in glaucoma.
  • Further research into these methods is warranted for clinical application in glaucoma treatment.